Welcome to our dedicated page for Orexo Ab news (Ticker: ORXOF), a resource for investors and traders seeking the latest updates and insights on Orexo Ab stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Orexo Ab's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Orexo Ab's position in the market.
Orexo AB (OTCQX: ORXOY) has announced positive results from a preclinical pharmacokinetic study using its AmorphOX® technology to develop intranasal formulations of semaglutide. The study compared three powder-based intranasal formulations with oral (Rybelsus®) and injectable (Wegovy®) versions.
Two of the AmorphOX powder formulations demonstrated a sevenfold increase in plasma values compared to the oral tablet, with lower variability in plasma concentration. While the intranasal formulations showed lower values than injectable delivery, they offer potential advantages including needle-free administration, no refrigeration requirements, and possibly extended dosing schedules.
The successful formulation of large peptides like semaglutide supports Orexo's updated strategy to focus on larger molecules including peptides, proteins, and vaccines.
FAQ
What is the current stock price of Orexo Ab (ORXOF)?
What is the market cap of Orexo Ab (ORXOF)?
